EFFICACY OF TARGET THERAPY WITH CRIZOTINIB IN A PATIENT WITH ALK-POSITIVE ADVANCED GASTRIC CANCER
A. A. Paichadze, 
L. V. Bolotina,
E. Y. Karpenko,
T. V. Ustinova,
A. L. Kornietskaya,
A. D. Kaprin,
A. A. Fedenko
L. V. Bolotina,
E. Y. Karpenko,
T. V. Ustinova,
A. L. Kornietskaya,
A. D. Kaprin,
A. A. Fedenko https://doi.org/10.21294/1814-4861-2020-19-1-141-146
Abstract
Although many currently known molecular targets are characterized by organ specificity, they can be found in various types of tumors. Molecular diagnostic techniques can be used to help select patients who are most likely to benefit from target therapy.
Case presentation. We describe the case of a 38-year-old patient with advanced gastric cancer with peritoneal dissemination. On december 11, 2014, the patient underwent palliative subtotal gastrectomy followed by 18 cycles of chemotherapy (xelOx) and radiotherapy. On February 2, 2017, percutaneous transhepatic cholangiostomy of the left lobe bile duct was performed. in May 2017, the stent was inserted into the common bile duct due to bile duct stenosis. three months later, disease progression (multiple liver metastases) occurred, and chemotherapy with paclitaxel was given in a weekly schedule. therapy with crizotinib was administered 3 months after determining the alK mutation. the duration of treatment was 8 months with satisfactory tolerability.
Conclusion. target therapy with krizotinib seems to be an effective treatment for alK-positive tumors.
About the Authors
A. A. Paichadze
National Research Medical Radiological Center, Ministry of Healthcare of Russian Federation
Russian Federation
Russian Federation
MD, PhD, Researcher, Chemotherapy Department
3, 2-nd Botkinsky proezd, 125284-Moscow, Russia
L. V. Bolotina
National Research Medical Radiological Center, Ministry of Healthcare of Russian Federation
Russian Federation
MD, DSc, Head of Chemotherapy Department
3, 2-nd Botkinsky proezd, 125284-Moscow, Russia
Russian Federation
MD, DSc, Head of Chemotherapy Department
3, 2-nd Botkinsky proezd, 125284-Moscow, Russia
E. Y. Karpenko
National Research Medical Radiological Center, Ministry of Healthcare of Russian Federation
Russian Federation
MD, Junior Researcher, Department of Chemotherapy
3, 2-nd Botkinsky proezd, 125284-Moscow, Russia
Russian Federation
MD, Junior Researcher, Department of Chemotherapy
3, 2-nd Botkinsky proezd, 125284-Moscow, Russia
T. V. Ustinova
National Research Medical Radiological Center, Ministry of Healthcare of Russian Federation
Russian Federation
MD, Medical Oncologist, Chemotherapy Department
3, 2-nd Botkinsky proezd, 125284-Moscow, Russia
Russian Federation
MD, Medical Oncologist, Chemotherapy Department
3, 2-nd Botkinsky proezd, 125284-Moscow, Russia
A. L. Kornietskaya
National Research Medical Radiological Center, Ministry of Healthcare of Russian Federation
Russian Federation
MD, PhD, Senior Researcher, Department of Chemotherapy
3, 2-nd Botkinsky proezd, 125284-Moscow, Russia
Russian Federation
MD, PhD, Senior Researcher, Department of Chemotherapy
3, 2-nd Botkinsky proezd, 125284-Moscow, Russia
A. D. Kaprin
National Research Medical Radiological Center, Ministry of Healthcare of Russian Federation
Russian Federation
MD, DSc, Member of the Russian Academy of Sciences, Director
3, 2-nd Botkinsky proezd, 125284-Moscow, Russia
Russian Federation
MD, DSc, Member of the Russian Academy of Sciences, Director
3, 2-nd Botkinsky proezd, 125284-Moscow, Russia
A. A. Fedenko
National Research Medical Radiological Center, Ministry of Healthcare of Russian Federation
Russian Federation
MD, DSc, Head of Chemotherapy Department
3, 2-nd Botkinsky proezd, 125284-Moscow, Russia
Russian Federation
MD, DSc, Head of Chemotherapy Department
3, 2-nd Botkinsky proezd, 125284-Moscow, Russia
References
1. Hyman D.M., Puzanov I., Subbiah V., Faris J.E., Chau I., Blay J.Y., Wolf J., Raje N.S., Diamond E.L., Hollebecque A., Gervais R., Elez-Fernandez M.E., Italiano A., Hofheinz R.D., Hidalgo M., Chan E., Schuler M., Lasserre S.F., Makrutzki M., Sirzen F., Veronese M.L., Tabernero J., Baselga J. Vemurafenib in Multiple Nonmelanoma Cancers with BRAFV600 Mutations. N Engl J Med. 2015 Aug 20; 373(8): 726–36. doi: 10.1056/NEJMoa1502309.
2. Protsenko S.A., Semionova A.I., Komarov Y.I., Aleksakhina S.N., Ivantsov A.O., Iyevleva A.G., Imyanitov E.N. BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment. Invest New Drugs. 2015 Oct; 33(5): 1136–43. doi: 10.1007/s10637-015-0280-0.
3. Shiota M., Mori S. The clinicopathological features of anaplastic large cell lymphomas expressing p80NPM/ALK. Leuk Lymphoma. 1996; 23: 25–32. doi: 10.3109/10428199609054798.
4. Morris S.W., Kirstein M.N., Valentine M.B., Dittmer K.G., Shapiro D.N., Saltman D.L., Look A.T. Fusion of а kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin/s lymphoma. Science. 1994; 263: 1281–4. doi: 10.1126/science.8122112.
5. Bischof D., Pulford K., Mason D.Y., Morris S.W. Role of the nucleophosmin (NPM) portion of the non-Hodgkin/s lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol. 1997; 17: 2312–25. doi: 10.1128/mcb.17.4.2312.
6. Shiota M., Nakamura S., Ichinohasama R., Abe M., Akagi T., Takeshita M., Mori N., Fujimoto J., Miyauchi J., Mikata A., Nanba K., Takami T., Yamabe H., Takano Y., Izumo T., Nagatani T., Mohri N., Nasu K., Satoh H., Katano H., Fujimoto J., Yamamoto T., Mori S. Anaplastic large celrrol lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood. 1995; 86: 1954–60.
7. Mossé Y.P., Laudenslager M., Longo L., Cole K.A., Wood A., Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P., Laureys G., Speleman F., Kim C., Hou C., Hakonarson H., Torkamani A., Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M., Maris J.M. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008 Oct 16; 455(7215): 930–5. doi: 10.1038/nature07261.
8. Pulford K., Morris S.W., Turturro F. Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol 2004; 199: 330–58. doi: 10.1002/jcp.10472.
9. Palmer R.H., Vernersson E., Grabbe C., Hallberg B. Anaplastic lymphoma kinase: signaling in development and disease. Biochem J. 2009; 420: 345–61. DOI: 10.1042/BJ20090387.
10. George R.E., Sanda T., Hanna M., Fröhling S., Luther W.2nd, Zhang J., Ahn Y., Zhou W., London W.B., McGrady P., Xue L., Zozulya S., Gregor V.E., Webb T.R., Gray N.S., Gilliland D.G., Diller L., Greulich H., Morris S.W., Meyerson M., Look A.T. Activating mutations in ALKprovide a therapeutic target in neuroblastoma. Nature. 2008 Oct 16; 455(7215): 975–8. doi: 10.1038/nature07397.
11. Lin E., Li L., Guan Y., Soriano R., Rivers C.S., Mohan S., Pandita A., Tang J., Modrusan Z. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res. 2009 Sep; 7(9): 1466–76. doi: 10.1158/1541-7786.MCR-08-0522.
12. Chiarle R., Voena C., Ambrogio C., Piva R., Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008; 8: 11–23. doi: 10.1038/nrc2291.
13. Lee J., Lee S.E., Kang S.Y., Do I.G., Lee S., Ha S.Y., Cho J., Kang W.K., Jang J., Ou S.H., Kim K.M. Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer. 2013 May; 119(9): 1627–35. doi: 10.1002/cncr.27967.
14. Peng Z., Li Z., Gao J., Lu M., Gong J., Tang E.T., Oliner K.S., Hei Y.J., Zhou H., Shen L. Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. Mol Cancer Ther. 2015 Nov; 14(11): 2634–41. doi: 10.1158/1535-7163.MCT-15-0108.
15. Graziano F., Humar B., Guilford P. The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. Ann Oncol. 2003 Dec; 14(12): 1705–13. doi: 10.1093/annonc/mdg486.
Review
For citations:
Paichadze A.A., Bolotina L.V., Karpenko E.Y., Ustinova T.V., Kornietskaya A.L., Kaprin A.D., Fedenko A.A. EFFICACY OF TARGET THERAPY WITH CRIZOTINIB IN A PATIENT WITH ALK-POSITIVE ADVANCED GASTRIC CANCER. Siberian journal of oncology. 2020;19(1):141-146. (In Russ.) https://doi.org/10.21294/1814-4861-2020-19-1-141-146
Views:
1656
Email this article 
